Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections

We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Sweeney, Daniel A, Tuyishimire, Bonifride, Ahuja, Neera, Beigel, John H, Beresnev, Tatiana, Cantos, Valeria D, Castro, Jose G, Cohen, Stuart H, Cross, Kaitlyn, Dodd, Lori E, Erdmann, Nathan, Fung, Monica, Ghazaryan, Varduhi, George, Sarah L, Grimes, Kevin A, Hynes, Noreen A, Julian, Kathleen G, Kandiah, Sheetal, Kim, Hannah Jang, Levine, Corri B, Lindholm, David A, Lye, David C, Maves, Ryan C, Oh, Myoung-don, Paules, Catharine, Rapaka, Rekha R, Short, Willam R, Tomashek, Kay M, Wolfe, Cameron R, Kalil, Andre C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191442/
https://www.ncbi.nlm.nih.gov/pubmed/37206623
http://dx.doi.org/10.1093/ofid/ofad205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191442/
https://www.ncbi.nlm.nih.gov/pubmed/37206623
http://dx.doi.org/10.1093/ofid/ofad205

Ejemplares similares